Abstract
Radiotherapy is one of the treatment options for locally or regionally advanced prostate cancer, but radioresistance of prostate cancer cells is a practical limitation of radiotherapy. The identification of molecular targets of radioresistance in prostate cancer is important to improve therapeutic intervention. The aim of this review is to give more biological insight into some well known processes involved in radioresistance of prostate cancer especially Apoptotic pathway; DNA damage response; and NF-κB(nuclear factor kappalight- chain-enhancer of activated B cells) signaling pathway. This review integrates salient, published, research findings with underlying molecular mechanisms, preclinical efficacy, and potential clinical applications of combining radiotherapy with these molecular targeted agents for the treatment of prostate cancer.
Keywords: Prostate cancer, radiotherapy, radiosensitization
Current Pharmaceutical Design
Title:Targeted Radiosensitization in Prostate Cancer
Volume: 19 Issue: 15
Author(s): Veerander P.S. Ghotra, Albert A. Geldof and Erik H.J. Danen
Affiliation:
Keywords: Prostate cancer, radiotherapy, radiosensitization
Abstract: Radiotherapy is one of the treatment options for locally or regionally advanced prostate cancer, but radioresistance of prostate cancer cells is a practical limitation of radiotherapy. The identification of molecular targets of radioresistance in prostate cancer is important to improve therapeutic intervention. The aim of this review is to give more biological insight into some well known processes involved in radioresistance of prostate cancer especially Apoptotic pathway; DNA damage response; and NF-κB(nuclear factor kappalight- chain-enhancer of activated B cells) signaling pathway. This review integrates salient, published, research findings with underlying molecular mechanisms, preclinical efficacy, and potential clinical applications of combining radiotherapy with these molecular targeted agents for the treatment of prostate cancer.
Export Options
About this article
Cite this article as:
P.S. Ghotra Veerander, A. Geldof Albert and H.J. Danen Erik, Targeted Radiosensitization in Prostate Cancer, Current Pharmaceutical Design 2013; 19 (15) . https://dx.doi.org/10.2174/1381612811319150017
DOI https://dx.doi.org/10.2174/1381612811319150017 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Biology Aspects of Computational Methods & Applications in Drug Discovery
Current Pharmaceutical Design Breakthrough Pain
Current Drug Therapy Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry Environmental Chemicals and Breast Cancer Risk – A Structural Chemistry Perspective
Current Medicinal Chemistry Technetium Labeled Small Peptide Radiopharmaceuticals in the Identification of Lung Cancer
Current Pharmaceutical Design Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Regulation of ABC Transporter Function Via Phosphorylation by Protein Kinases
Current Pharmaceutical Biotechnology HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design Current and Future Development of Estrogen Receptor Ligands: Applications in Estrogen-Related Cancers
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Tumor Stroma Manipulation By MSC
Current Drug Targets Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry STAT Signaling and Cell Function
Current Genomics Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer
Current Pharmaceutical Design Venous Collateral Circulation of the Extracranial Cerebrospinal Outflow Routes
Current Neurovascular Research Small-Molecule CSF1R Inhibitors as Anticancer Agents
Current Medicinal Chemistry